Pericoronary Adipocyte Size Gradient
AdipoCor
Direct Measurement of Pericoronary Adipocyte Size Gradient as a Parameter of Immunometabolic Changes of Perivascular Adipose Tissue
1 other identifier
observational
60
1 country
1
Brief Summary
Evaluation of pericoronary adipocyte gradient (PCAT) in relationship with local atherosclerotic changes in a patient undergoing heart transplantation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jun 2023
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2023
CompletedFirst Submitted
Initial submission to the registry
January 6, 2026
CompletedFirst Posted
Study publicly available on registry
January 22, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2029
January 22, 2026
January 1, 2026
5.1 years
January 6, 2026
January 14, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Adipocyte size
Assessment of the difference (in square micrometer) between adipocyte size closely adjacent to the coronary artery and those more distant from the arterial lumen in relation to atherosclerotic pathologies in situ
Perioperative/Periprocedural
Secondary Outcomes (2)
Immunological parameters
Perioperative/Periprocedural
Morphological parameters
Perioperative/Periprocedural
Study Arms (1)
patients with advanced heart failure
A group of patients with advanced heart failure were indicated for heart transplanta-tion for either ischemic or dilatational cardiomyopathy. The study group will also in-clude subjects with previously implanted LVAD as a bridge-to-transplant approach. Predictory-related subgroups will be evaluated separately.
Interventions
The study population comprises patients who underwent heart transplantation for heart failure at the Institute for Clinical and Experimental Medicine, Cardiovascular Surgery Department, between June 2023 and December 2028. Only the subjects' retrospective clinical data and matching heart samples will be analyzed.
Eligibility Criteria
The study population comprises patients who underwent heart transplantation for heart failure at the Institute for Clinical and Experimental Medicine, Cardiovascular Surgery Department, between June 2023 and December 2028. Only the subjects' ret-rospective clinical data and matching heart samples will be analyzed.
You may qualify if:
- Age 30-90 years
- Diagnosis of dilatational or ischemic cardiomyopathy
- Patients undergoing heart transplantation in IKEM
You may not qualify if:
- Known combined diagnosis of dilatational and ischemic cardiomyopathy
- Arrhythmogenic cardiomyopathy
- Congenital heart defects
- Non-eligibility due to the absence of informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centre of Experimental Medicine, Institute for Clinical and Experimental Medicine,
Prague, 14021, Czechia
Biospecimen
Coronary artery segment with adjacent tissues
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Ivana Kralova Lesna, M.D., PhD., assoc. prof.
Study Record Dates
First Submitted
January 6, 2026
First Posted
January 22, 2026
Study Start
June 1, 2023
Primary Completion (Estimated)
July 1, 2028
Study Completion (Estimated)
July 1, 2029
Last Updated
January 22, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share